Monte Rosa Therapeutics, Inc. Stock Price, News & Analysis

BOSTON, Feb. 3, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (NASDAQ: GLUE) is set to participate in several investor events, showcasing its advancements in molecular glue degrader (MGD) therapies. Key events include:

• Guggenheim Oncology Conference on February 9, 2023, at 2:45 p.m. ET
• BMO Virtual Biopharma Spotlight on February 10, 2023, at 10:00 a.m. ET
• SVB Securities Global Biopharma Conference on February 14, 2023, at 11:20 a.m. ET
• Wells Fargo Targeted Protein Degradation Summit on February 21, 2023, at 3:00 p.m. ET
• Cowen’s 43rd Annual Health Care Conference on March 7, 2023, at 10:30 a.m. ET

Webcasts will be available on the company's investor site.

Monte Rosa Therapeutics (NASDAQ: GLUE) announced key milestones for 2023, including FDA's Fast Track designation for MRT-2359 aimed at treating previously treated, metastatic non-small cell lung cancer (NSCLC) expressing L-MYC or N-MYC. Initial data from the ongoing Phase 1/2 trial is expected in H2 2023, alongside the nomination of additional development candidates. The company will present updates at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023.

BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics (NASDAQ: GLUE), a biotechnology company focused on novel molecular glue degrader (MGD)-based medicines, announced that CEO Markus Warmuth is set to present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 11:15 a.m. PT. The presentation will be accessible via the company’s investor site, with an archived version available for 90 days.

Monte Rosa's innovative approach utilizes a proprietary platform called QuEEN™ to identify therapeutic protein targets for drug development.

Monte Rosa Therapeutics (GLUE) announced significant advancements in its clinical programs, including the initiation of patient dosing for MRT-2359, a GSPT1-directed molecular glue degrader targeting MYC-driven tumors. The company reported a net loss of $27.3 million for Q3 2022, up from $19.8 million in Q3 2021. R&D expenses rose to $21.3 million due to expanded activities in MRT-2359 and the QuEEN™ platform. As of September 30, 2022, Monte Rosa maintains a cash position of $277.4 million, expected to support operations until late 2024.

Monte Rosa Therapeutics (NASDAQ: GLUE) has initiated dosing for its Phase 1/2 clinical trial of MRT-2359, targeting MYC-driven solid tumors like lung cancer. This investigational drug is a selective molecular glue degrader aimed at disrupting protein synthesis in these tumors. The trial's primary focus will be on safety, tolerability, and preliminary anti-tumor activity, with a concentration on cancer types characterized by prevalent MYC expression. The Chief Medical Officer emphasized the significance of this milestone, motivated by strong preclinical data and a commitment to improving patient outcomes.

Monte Rosa Therapeutics (NASDAQ: GLUE), a biotechnology firm focused on developing innovative molecular glue degrader-based therapies, has announced its participation in several upcoming investor conferences. These include the Credit Suisse 31st Annual Healthcare Conference from November 7-10, the Jefferies 13th Annual London Healthcare Conference from November 15-17, and the Piper Sandler 34th Annual Healthcare Conference from November 29 to December 1. Archived webcasts will be available on the company's investor site.

Monte Rosa leverages its proprietary QuEEN™ platform for protein degradation in drug discovery.

Monte Rosa Therapeutics (NASDAQ: GLUE) announced new preclinical data for MRT-2359, a GSPT1-directed molecular glue degrader targeting MYC-driven cancers. This data will be presented at the 5th Annual Targeted Protein Degradation Summit on October 25-28 in Boston and the EORTC-NCI-AACR Symposium in Barcelona on October 26-28. CEO Markus Warmuth highlighted the drug's ability to degrade GSPT1, enhancing anti-tumor activity. The company will also showcase its AI and machine learning capabilities aimed at novel MGD design.

Monte Rosa Therapeutics (NASDAQ: GLUE) announced FDA clearance for its investigational new drug application for MRT-2359, a molecular glue degrader targeting MYC-driven solid tumors. The Phase 1/2 clinical trial is set to commence in Q4 2022, marking a significant milestone for the company. MRT-2359 aims to disrupt GSPT1 protein synthesis, a critical factor in tumor growth, offering new treatment options for patients with limited alternatives. This advancement validates Monte Rosa's unique approach to protein degradation.

Monte Rosa Therapeutics (NASDAQ: GLUE) announced its submission of an Investigational New Drug (IND) application for MRT-2359, a GSPT1-directed molecular glue degrader targeting Myc-driven solid tumors. The company reported a net loss of $26.5 million for Q2 2022 and R&D expenses of $20.9 million, up from $14.6 million YoY, due to expanded activities. Monte Rosa holds $299.5 million in cash and equivalents, providing a cash runway into late 2024. Upcoming milestones include a Phase 1/2 trial initiation for MRT-2359, expected in Q4 2022 pending FDA clearance.